Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile

Review

Abstract: inTrodUCTion: The management of non-metastatic castration-resistant prostate cancer (nmCrpC) has und

Palabras claves:

Apalutamide, Castration, Darolutamide, Enzalutamide, Network meta-analysis, prostatic neoplasms

Autores:

Briganti A., Diego M. Carrión, Egawa S., Esperto F., Fiori C., Grossmann N.C., Katayama S., Kimura T., Laukhtina E., Mori K., Mostafaei H., Motlagh R.S., Papalia R., Ploussard G., Pradere B., Quhal F., Rajwa P., Schuettfort V.M., Shariat S.F.

Fuentes:

scopus